Four Peptides, Three Combinations
The tissue-repair blends sold across this industry are drawn from a small pool: BPC-157, thymosin β4, GHK-Cu and KPV. The three we stock are different selections from that pool.
- Wolverine — BPC-157 + TB-500. The minimal pairing.
- GLOW — BPC-157 + TB-500 + GHK-Cu. Adds the copper peptide.
- KLOW — KPV + GHK-Cu + BPC-157 + TB-500. Adds the anti-inflammatory tripeptide on top.
Each component has its own literature and its own proposed mechanism. None of the three combinations has published pharmacology of its own, and no study we are aware of demonstrates synergy between them. A blend is a packaging convenience, and it is worth being clear about that before choosing one.
What Each Component Contributes
BPC-157 is a 15-residue synthetic peptide derived from a human gastric juice protein, studied for effects on angiogenesis, VEGFR2 signalling and nitric-oxide pathways. Much of its literature originates from a single research group, and independent replication remains limited — a known weakness of the evidence base rather than a criticism of the material.
Thymosin β4 is a 43-residue endogenous actin-sequestering protein studied in cell migration and wound closure. It is not a designed drug-like peptide; it is a protein the body already makes.
GHK-Cu is the copper(II) complex of the plasma tripeptide glycyl-L-histidyl-L-lysine, studied for collagen and glycosaminoglycan synthesis and matrix remodelling, largely through copper delivery to enzymes such as lysyl oxidase.
KPV is the C-terminal tripeptide of α-MSH — residues 11 to 13. It retains the parent hormone's reported anti-inflammatory activity without its melanocortin-receptor pigmentation effects, which is why the fragment is used rather than the whole hormone.
Why the Mass Ratio Misleads
This is the point most often missed. These peptides differ enormously in molecular weight, so equal masses are nowhere near equal molar amounts.
- KPV — 342.43 g/mol
- GHK-Cu — 401.91 g/mol
- BPC-157 — 1419.53 g/mol
- Thymosin β4 — 4963.44 g/mol
Thymosin β4 is roughly fourteen times heavier than KPV. In GLOW, where GHK-Cu makes up 50 of the 70 mg, the copper peptide is present in very large molar excess — far more so than the mass figures suggest. In KLOW, equal 10 mg amounts of KPV, BPC-157 and thymosin β4 are about 29, 7 and 2 µmol respectively.
If your concentration range is calculated from total vial mass, you are not dosing what you think you are dosing. Work from the per-component amounts on the certificate.
What the Certificate Tells You
The components separate cleanly under reverse-phase HPLC — GHK-Cu elutes early, BPC-157 in the middle, thymosin β4 later — so a batch certificate reports purity and content per peak rather than one combined figure. That is the only way a blend certificate is meaningful, and it is worth checking you have one before trusting a blended lot. Look yours up in the COA verification hub.
One compositional caveat on our own listing: the certificates for the Wolverine blend state the total vial mass but not the split between BPC-157 and thymosin β4. We show an even split and have flagged it as unconfirmed rather than presenting an assumption as fact.
The Copper Complication
Any blend containing GHK-Cu inherits two handling constraints the other components do not have.
Chelators strip the copper. EDTA and similar agents will pull Cu(II) out of the complex, leaving free GHK. If your buffer contains a chelator — and many standard buffers do — you are no longer studying GHK-Cu.
Light matters. Copper complexes should be protected from light in solution. The characteristic blue colour of GHK-Cu powder, and the pale blue of GLOW and KLOW, comes from Cu(II) absorbing in the orange-red; losing that colour is a visible warning sign.
Mass spectrometry adds a third wrinkle: under electrospray conditions the complex can partially dissociate, so spectra may show free GHK near 340.4 Da alongside the intact complex. That is expected behaviour, not a purity failure.
When Not to Use a Blend
A blend's ratio is fixed at manufacture. You cannot vary one component, you cannot run a dose–response on one component, and you cannot attribute an effect to one component.
So: if your question is mechanistic — does this peptide do this thing — use single-compound vials. BPC-157, TB-500 and GHK-Cu are all stocked individually, and KPV is available inside KLOW.
If your question is about the combination as it is actually used, a blend is the right format and saves reconstituting three vials. GLOW is the common middle choice; Wolverine is the minimal one.
Our comparison of BPC-157 and TB-500 mechanisms goes further into the two peptides every one of these blends contains.
Frequently Asked Questions
What is the difference between GLOW and KLOW?
KLOW is GLOW with KPV added. GLOW is BPC-157, TB-500 and GHK-Cu; KLOW adds the α-MSH (11-13) tripeptide, which has a separate anti-inflammatory literature from the matrix-remodelling work behind the other three.
Do the components in these blends work synergistically?
No published evidence establishes synergy. Each component has its own literature and its own proposed mechanism, and the combinations have no published pharmacology of their own. The rationale is additive coverage of related pathways, not a demonstrated interaction.
Why does the molar ratio differ so much from the mass ratio?
Because the components differ by more than fourteen-fold in molecular weight. Thymosin β4 is 4963.44 g/mol against KPV's 342.43, so equal masses are very unequal molar amounts. Calculate from per-component amounts, not total vial mass.
Can I use EDTA buffer with GLOW or KLOW?
Not if GHK-Cu matters to your experiment. EDTA and similar chelators strip Cu(II) from the complex, leaving free GHK — a different molecule with different behaviour.
References & Further Reading
Sikiric P et al., Curr Pharm Des 2018; Goldstein AL, Hannappel E, Kleinman HK, Trends Mol Med 2005; Pickart L, Margolina A, Int J Mol Sci 2018; Dalmasso G et al., Am J Physiol Gastrointest Liver Physiol 2008 (KPV).